Pharmion/MethylGene begin combined MGCD0103/Vidaza trial
USA-based drugmaker Pharmion and Canada's MethylGene have begun enrollment in a Phase II trial evaluating MGCD0103 in lymphoma. Specifically, MGCD0103, which is a histone deacetylase inhibitor being co-developed by the two firms (Marketletter February 6, 2006), will be examined in combination with the former's DNA demethylating agent Vidaza (azacitidine) in patients with relapsed or refractory Hodgkin's or non-Hodgkin's lymphoma. MGCD0103 has been designated an Orphan Drug/Medicinal product for the former indication by the Food and Drug Administration and the European Medicines Agency (EMEA), respectively.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze